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ABSTRACT
At the turn of the 21st century, much like the turn of the 20th century there has
been a major shift in North America with its industries and their impact on the landscape.
With a trend of massive deindustrialization of large-scale production facilities throughout
the (Gibbs 2003, 222-236) United States, it has directly impacted the landscape. There
are currently changes underway in the American industrial landscape emphasizing a new
technology whereby pharmaceuticals are manufactured in recombinant plants. These
plant-derived pharmaceuticals are poised to become the next major part of the
pharmaceutical industry. By recognizing the potential and studying the possible shapes
and connections we can begin to visualize, develop and improve the outcomes of a new
economy focused on plant derived compounds. It is the intent of this research to
investigate the Clemson University community’s perception of these genetically modified
plants when put into a curative context. Although genetically modified organisms have
been put in a negative light over the past 15 years, when put into a curative context they
will have a higher rate of support. Through thoughtful design, the curative potential of
these genetically modified plants may be revealed to the public and surrounding
community fostering good will between industry and the community as well as offering
recreational and educational opportunities to the public along with on site employees. It is
also the intent of this research to demonstrate that through building upon an interchange
of material and energy flows (Gibbs 2003, 222-236) beginning with pharmaceutical
production in plants, a local or regional industrial ecosystem hinging on health can be
implemented. The design of such an ecosystem, regardless of size, has the potential to
reshape the American industrial landscape. This information may then help guide design
decisions in creating an industrial landscape for the future.
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CHAPTER ONE
INTRODUCTION
Changes in the American landscape have been dominated by deindustrialization
in the past decades (Bélanger 2009, 79-95; Isaksen 1997, 65-76; Rodwin and Sazanami
1989). Deindustrialization is defined as the long-term decline in employment in the
manufacturing sector (Rodwin and Sazanami 1989; Rowthorn and Ramaswamy 1997).
There has been a shift from the large planned, centralized industries of mass production
to a more decentralized system (Isaksen 1997, 65-76). The landscape has the ability to
affect humans in many ways from how land is viewed aesthetically to how it affects
health and emotional states (Velarde, Fry, and Tveit 2007, 199-212)and how the land is
used functionally (Phillips 1998). There are many aspects to consider from
deindustrialization including reclamation and reuse of brownfield sites, environmental
concerns for abandoned sites (Bluestone and Harrison 1982), massive layoffs(Perrucci et
al. 1988), changing economic structures (McKenzie and Welch 1984; Rodwin and
Sazanami 1989) and community abandonment (Bluestone and Harrison 1982), however
this research is focused on the role new technology can play in rethinking the industrial
landscape.
Though the United States has seen a decline in mass-produced goods (Feenstra
1998, 31-50; Staudohar and Brown 1987), today, the United States is the world leader in
biotechnology (Pharmaceutical Research and Manufacturers of America (PhRMA)
2010). American biotech companies account for 80% of research and development
worldwide(Pharmaceutical Research and Manufacturers of America (PhRMA) 2010). In
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1992, a group of American scientists produced a vaccine for Hepatitis B in a genetically
modified tobacco plant demonstrating that plants have the ability to produce relevant
pharmaceutical compounds (Mason, Lam, and Arntzen 1992, 11745). Genetically
modified plants (GMPs) are plants that contain an additional trait determined by
introduced genes, which typically produce additional proteins (Ahmed 2002, 215-223).
Currently there are 213 drug shortages in the United States alone (fda.gov). With a new
method of production available, plant derived pharmaceuticals have the potential to
alleviate an array of problems faced by the country as a whole. By focusing on the public
perception of genetically modified plants and understanding the various forms and
functions of past industrial and healing landscapes we may then begin to design and
envision a new industrial landscape, one that not only produces healing compounds but
promotes general well being, reveals and illuminates the benefits of new technologies,
creates educational opportunities for the public to learn about new technologies such as
plant manufactured pharmaceuticals and generates feelings of connection and good will
between industry and the public.
Since the United States is a leader in biotechnology research and advancements
(Pharmaceutical Research and Manufacturers of America (PhRMA) 2010), and though
there is now a large skilled but unemployed workforce due to loss of manufacturing to
overseas companies as well automated production practices (Berman, Bound, and
Griliches 1994), the United States should be well positioned to move into a new era of
American industry. The United States dominates the market for commercial application
of biotechnology research and findings (Shan and Song 1997, 267-284) although
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Americans are less able to actualize the important follow thorough in turning these
innovations into products and manufacturing processes required to turn new technology
into a constant stream of commercial products (Florida and Kenney 1990).

“The crux of the situation is that the U.S. technology system is heavily
biased in the direction of major new technological discoveries, or
breakthroughs.”

Florida and Kenney in The Breakthrough Illusion 1990

Florida stresses the importance of synergistic interactions between well-funded R&D and
integrated manufacturing. Without the integrated manufacturing, we do not have the
ability to capitalize on our innovations. What does this mean for the United States? There
is a new technology, a breakthrough, in plant-derived pharmaceuticals. There has been a
loss of manufacturing jobs due to massive deindustrialization (Feenstra 1998, 31-50) and
we have a large number of drug shortages in the United States, but we are the world
leader in biotechnology (Pharmaceutical Research and Manufacturers of America
(PhRMA) 2010). By using GMPs and plant-derived pharmaceuticals as the catalyst, a
new form of industry can evolve.
Through understanding the role of plant derived pharmaceuticals in a new
industrial landscape, it provides the opportunity to answer many of the challenges that are
faced today and to change the approach to health care, specifically during diagnosis and
treatment. By taking a collaborative approach and encouraging links between different
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sectors of the industry, in this case diagnostic and pharmaceuticals, this study propose
that the collaboration can spill into other areas and promote better communication
between sectors where each can benefit from this increased collaboration and
communication.
This research proposal seeks to determine how emerging technology has shaped
our industrial landscape over the past century and to understand what a new landscape
with plants as the main production engine would look like. Specifically, this study
focuses on the perception of genetically modified plants and the design implications that
result from these perceptions. It is proposed that if the potential of a new technology in
plant derived pharmaceuticals is recognized, public perceptions of using this new
technology are understood and the implementation of such an industry is well planned
and deliberate, the power of integrated manufacturing, of turning a new technology into a
commercial application may then be harnessed. By understanding, planning and
designing for this new technology in advance, then the concepts of industrial ecology and
consumer experience tourism can be applied to maximize the benefits by linking
industries to each other and their and communities.
The site in this research study is an agricultural campus in Charleston, SC focused
on research, small-scale production, process development, education and public outreach,
this study will help poise pharmaceutical and diagnostic companies for large scale
applications of this new technology. America will have the ability to take this
breakthrough, and channel it’s potential into a new industrial landscape
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CHAPTER TWO
LITERATURE REVIEW

Industrial Landscapes and Industrial Ecology
The American industrial landscape has seen a shift in the past 30 years due to
massive deindustrialization (Bluestone and Harrison 1982; McKenzie and Welch 1984;
Patch 1995). This shift provides an opportunity to examine the previous model of
industry, the planned industrial district and single use zoning from the turn of the 20th
century and propose needed changes. Learning from and then understanding the longterm effects of industrialization at urban and regional scales can help shape the landscape
in an economically and environmentally sensitive manner. This emerging field of
industrial ecology is an approach to industry that introduces a change to both product and
environmental focuses from a linear to a materials cycle approach (Graedel, Allenby, and
Linhart 1993, 18-26). It places equal importance on economic development and
environmental quality (http://cie.research.yale.edu/).

Figure 1: Industrial ecology in practice at Kalundborg, Denmark (http://newcity.ca/Media/Kalundborg.gif)
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Industrial ecology takes the industrial district and attempts to understand the
potential for environmental improvements where both the processes and the industries are
viewed as systems that interact (Gibbs 2003, 222-236). Gibbs also states that this
provides a way to connect systems through process outputs or industries into a web that is
designed to minimize waste. By locating a cancer research and small-scale production
facility in the West Ashley district of Charleston, South Carolina, exploration into the
industrial ecological relationships that might form through the planning and design of a
research campus may begin.
In order to move towards a system where industrial relationships are more
symbiotic, the history of the American industrial landscape must be explored. Industrial
districts and parks shaped the industrial landscape of the 20th century. Industrial parks
have been single zone places of economic activity since as early as 1905 (Lewis 2004,
29-49). Recently there has been a push to make them sustainable eco-parks, but the
design of the parks as compared to traditional industrial parks has not seen major
changes(Peddle 1993, 107-124). Peddle also noted that the Urban Land Institute updated
the title of the handbook on industrial development from simply the Industrial
Development Handbook to the Business and Industrial Park Development Handbook
with little changes to the subject matter. These eco-industrial parks are co-dependent
through shared processes or waste cycling, but it ends there. One may use the by-products
of the other but there have yet to be cases documented where products from initial
conception (research and development) to production (manufacturing) to consumer, in
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this particular study where the patient would be the consumer with a medical professional
providing the diagnostic and therapeutic expertise.
Another factor influencing the industrial sector is the scale at which things are
now produced. As we move toward sustainable production and consumption, there have
been improvements in the processes and products (Isaksen 1997, 65-76). The mass
production economy of the United States has adopted the lean production ideas of Japan
(Robins and Kumar 1999, 75-94; Feenstra 1998, 31-50; Staudohar and Brown 1987).
These shifts in production can then begin to shape the physical layout of production
spaces where large swaths of buildings and land for single use mass production can be
shifted to smaller scale multi-dimensional sites where research, development, small scale
production, consumption and public education and outreach can all coexist. A
multilayered system has the ability to become more uniquely tailored toward industry
demands. The proposed site in Charleston at the Clemson University Coastal Research
and Education Center has the ability to encompass the whole. The scope of this project
will touch on the broad implications of an industrial ecosystem while focusing on the
design and implementation of a research campus with a public outreach and educational
component, a small but essential part to the health landscape.
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Plant Manufactured Pharmaceuticals
Plants have been used for centuries to cure and prevent disease, and recent
advances in biotechnology have been made to allow plant cells to produce complex
proteins (Ma et al. 2005, 580-585; Jamal et al. 2009, 7-12). These therapeutic proteins are
more commonly known by their pharmaceutical brand names like Herceptin, the breast
cancer treatment, Enebrel and Remicade for rheumatoid arthritis and Rituxan and
MabThera for non-Hodgkin’s lymphoma to list a few (Elbehri 2005; Jamal et al. 2009, 712). Plant manufactured pharmaceuticals are therapeutic compounds, including those
listed above, that are produced in genetically modified plants(Andrawiss 2006, 42-52).
These compounds have traditionally been produced through inoculating animals
or in the laboratory through mammalian cell culture techniques (Andrawiss 2006, 42-52).
Fischer et al. claim that we are facing a growing demand for protein therapeutics and
diagnostics with a shortage of facilities to produce such compounds. It is estimated that
up to 50% of therapeutic antibodies can be delayed in manufacturing due to lack of
capacity (Elbehri 2005). A shift to plants as the bioreactors would enable flexibility in
manufacturing, have a focus on target therapy with minimized side effects, save money
and increase capacity (Elbehri 2005).
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Genetically Modified Organisms and Public Perceptions
Genetically modified plants are created by altering the genetic material in a plant
to improve or to change its characteristics (Mitrovic and Tosic 2006). Perceptions of such
plants are important when proposing that manufacturing be moved from the laboratory to
the field. There have been a number of studies that show two things. One, that genetically
modified organisms (GMOs) have been seen in an increasingly negative light but the
other, that these GMOs are seen as advantageous if there are sufficient benefits (Hossain
et al. 2003, 353-365; Specter 2000, 58-71; Moon and Balasubramanian 2004, 186-208),
Hossain et al. report that less than 60% of Americans support the use of genetic
technology in food crops when there are no tangible benefits while that number increases
to over 80% when there are benefits like rice fortified with vitamin A called Golden Rice
(Hossain et al. 2003, 353-365), a huge public health victory when put in the following
context. A third of the world’s population relies on rice for a dietary staple but more than
100 million children worldwide suffer from Vitamin A deficiency. This deficiency leads
to loss of eyesight of millions and at least two million deaths due to other related
infections annually. With the introduction of Golden Rice, this product has the potential
to alleviate more suffering than what any other single drug has accomplished over history
(Specter 2000, 58-71).
Another study delved further into public perception of agrobiotechnology
focusing on GM foods and found that lack of trust of governmental agencies coupled
with perceived involuntary exposure to risk were the driving forces behind viewing
GMOs in a negative light (Moon and Balasubramanian 2004, 186-208). This negativity
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may stem from an increased perception of risk due to lack of trust in federal regulators
along with negative reporting from the media (Nevitt et al. 2006; Hossain et al. 2003,
353-365).
An important point to these findings is that consumers tend to overestimate risk
when it is involuntary, and that a “right-to-know” provision and allowing consumers to
make an informed decision can alleviate these negative perceptions (Moon and
Balasubramanian 2004, 186-208). To date, few studies have been performed focusing on
GMOs used for pharmaceutical purposes. Nevitt et. al conducted a telephone survey to
gauge consumer response to plant derived pharmaceuticals produced in tobacco. The
findings showed support for plant derived pharmaceuticals when the plant alternative was
less expensive than the conventional pharmaceutical (Nevitt et al. 2006). Perceptions of
risk and other ethical concerns were offset by the perceived medicinal advantages
(Frewer et al. 2004, 1181-1193) and United States consumers supported agricultural
biotechnology applications for producing pharmaceuticals over using transgenic animals
(Hoban 1998; Falk et al. 2002, 1384-1390; Initiative 2004).
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Production Advantages and Concerns
There have been clear advantages to using plants as pharmaceutical production
systems documented, but there are also risks and regulatory hurdles that must be
considered (Kirk et al. 2005, 449-462). Advantages included in using plants as
bioreactors for pharmaceutical production are a drastic reduction in production costs
which have been calculated to save four to five times as compared to cell culture
production, large production capacity, faster scale up process, a variety of available plant
hosts, the ability to create specific, even patient specific antibodies quickly and
effectively, and high production levels from individual plants (Gomord et al. 2004, 83100). According to the phase I clinical study for the treatment of non-Hodgkin’s
lymphoma using plants as the bioreactor, the process allowed for the rapid production
and recovery of therapeutic antibodies derived from each patient’s tumor. This allowed
the patients to be immunized with a highly specific, individually tailored therapeutic
antigen (McCormick et al. 2008, 10131).
A plant derived pharmaceutical production system would also allow for
predominantly agricultural societies, particularly in developing countries, to improve
health by being able to produce therapies that control infectious diseases including but
not limited to HIV/AIDS, hepatitis B and cholera (Ma et al. 2005, 580-585). Although the
benefits are numerous, there are risks associated this new technology as there is with any
new technology. The risks include contamination of food crops, limited shelf life of some
crop types, and the current negative opinion of genetically modified crops, most notably
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in Europe (Fischer et al. 2004, 152-158; Ma et al. 2005, 580-585; Mihaliak et al. 2005,
158). Concern over any economic advantages to farmers or pharmaceutical consumers
has also been raised by a group called the Union of Concerned Scientists (Marris 2007, 99), however this group does not concentrate on the economic impact of the system as a
whole.
According to figures released by a Canadian insulin manufacturer one acre of
their transgenic safflower would give a yield of over 1 kilogram, enough to supply 2500
patients with insulin for the year (Lewcock 2007). With the world demand at 5000 kg and
expected to rise dramatically in the next decade, new production methods are needed.
Currently three suppliers control the majority of the world’s production of
pharmaceutical grade insulin and use traditional laboratory techniques producing insulin
through cell culture (Lewcock 2007).
Critics want plant manufactured pharmaceutical crops restricted to greenhouses
and non-food crops. Proponents say drug-producing plants can be safely grown outdoors
(Munro and Service 2007, B6). Greenpeace activists have expressed concern over
contamination of the food supply while scientists and supports argue that chemical
manipulation in the laboratory including intense purification cycles are required to
activate the proteins (Munro and Service 2007, B6). Simply put, the plants are the raw
material that still must be processed to harness the curative compounds.
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Therapeutic, Healing and Restorative Landscapes
Building upon the idea that an industrial landscape may potentially double as an
agricultural landscape, this study also introduces the idea that it could also be a
therapeutic or healing environment. As Wilbert Gesler succinctly put it in his book
Healing Places, place matters to health (Gesler 2003). He further argues that there is a
tendency to focus on current thinking while ignoring the influences of the past. Healing
environments have been a part of human history for thousands of years. The Temple of
Asclepius at Epidauros elegantly combined the natural, built and social environments into
a place of healing. The ecology of the buildings was one that invited learning, commerce,
healing and relaxing in one small area (Burford 1969; Gesler 1993, 171-171).
Healing environments have enjoyed a recent resurgence in study. Led by Roger
Ulrich’s study on views through windows influencing recovery from surgery, it has been
found that when subjects are exposed to views of nature recovery times are faster, stress
is reduced and attention levels are heightened (Ulrich 1981, 523-556; Ulrich 1984, 420;
Ulrich 1986, 29-44; Ulrich et al. 1991, 201-230).
Natural environments are more desirable and enhance stress recovery (Ulrich
1984, 420; Ulrich 1981, 523-556; Ulrich et al. 1991, 201-230; Ulam 2006, 46, 48-53;
Ulrich 1986, 29-44). Nature scenes included those dominated by vegetation including
cultivated fields and nature scenes with water have positive influences on emotional state
(Ulrich 1981, 523-556). Nature scenes including fields with high openness lead to high
levels of tranquility and low levels of feeling danger (Herzog and Chernick 2000, 29-39).
Leather et al. expanded on Ulrich’s 1984 work and found that it is not the level of
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illumination from windows that is most important for workers but the proportion of
natural elements they can see from the window (Leather et al. 1998, 739-762).
Other researchers have found that intense focus and long periods of directed
attention leads to fatigues but that restorative environments allow for a resting period
from this focus (Kaplan 1987, 3-32; Kaplan, Kaplan, and Brown 1989, 509-530; Kaplan
and Kaplan 1989; Kaplan 1993, 193-201; Russ 1991, 1-23). Such restorative
environments have four distinct features: being away, an ‘otherworldly’ quality (Kaplan
1995, 169-182), soft (or quiet) fascination, and compatibility (Herzog, Maguire, and
Nebel 2003, 159-170).
By including design elements found in therapeutic, restorative and healing
environments, the proposed research campus will incorporate multiple layers of healing,
revealing and illuminating from the actual pharmaceuticals produced to the nature of the
space. It is the intent of this research and design to create a healing landscape that not
only produces healing compounds, but gives respite to those who work and visit the
campus, providing a sanctuary for mind, body and spirit during the work day and beyond.
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Consumer Experience Tourism
Each of the following topics is important for the growth of a new industry in
plant-manufactured pharmaceuticals. By focusing on the perception of a new technology
and recognizing that there may be skepticism of new technologies, particularly in dealing
with genetically modified plants. By engaging the public and providing an opportunity to
understand the motivation, the process and the opportunities that lie behind the plant
manufactured pharmaceutical industry it is proposed that the venture will be more
successful. Through consumer experience tourism, which for this study will be defined as
an attempt to establish a bond or understanding between consumer and company, the
potential of new technologies can be introduced to the public as they learn about the
brand, the production process and any history associated with the industry or even the site
on which the plant is located (Mitchell and Mitchell 2001b, 1-16). Lukas notes “company
museums create the specter of the Wizard of Oz, but factory tours provide a glimpse of
the man behind the curtain” (Lukas 1998, 170-171).
Many companies have recognized the value in consumers bonding with brands
through plant tours or while visiting company museums or visitor centers(Mitchell and
Mitchell 2001b, 1-16). Having activities and spaces dedicated to public outreach and
education allow the company to fully share their message, and conveys a sense of
openness and transparency (Mitchell and Mitchell 2001a, 61-77).
Harris (Harris 1989, 38-42) and Prentice (Prentice 1993) note that factories and
mines historically employed a large percentage of the American workforce. In the shift
from a skilled manufacturing economy to a serviced based economy, a nostalgic view of
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industrial work has been created (Mitchell and Mitchell 2001a, 61-77). Rudd and Davis
point out that the Industrial Revolution defined much of American history (Rudd and
Davis 1998, 85-89) and companies that provide a glimpse into their manufacturing and
production processes speak to America’s industrial history while look forward to the
innovative future (Mitchell and Mitchell 2001a, 61-77). In short, a visitor center works to
promote education and foster good will between the public and a private business.
Campus tours clarify misconceptions and offer a level of transparency that in turn fosters
good relationships between private sector businesses and their surrounding communities.
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CHAPTER THREE
METHODOLOGY
The research questions were answered using a combination of qualitative and
quantitative research design strategies. The first strategy was in the form of case studies.
Studying specific examples from the bodies of knowledge reviewed in the literature helps
in understanding the different subjects and any connections they have with one another.
Because research is creating a set of patterns, there was a need to take parallel examples
to dissect and understand how they can help guide design decisions in rethinking
industry.
The second strategy was in the form of a survey containing questions to be
answered along the Likert scale. According to Punch, the purpose of a survey is to
quantitatively describe a sample in terms of proportions and percentages of people who
respond in this way or that to different questions (Punch and Punch 2005). The survey
was used to study the acceptance of genetically modified plants used to manufacture
pharmaceuticals amongst the Clemson University faculty, staff and students. The results
of the survey were used to inform design decisions of the proposed research campus.
By forming a holistic understanding of technology, the industrial landscape and
the interactions that all of the industries have with each other and the environment as well
as understanding the influence of both modern and ancient therapeutic landscapes, we
can then begin to envision an industrial landscape that is sustainable and healing on
multiple levels.
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Survey Plan of Work and Data Collection Methods
The population identified for the survey was the Clemson University population,
which includes faculty, staff and students. This survey aimed to find the current rate of
acceptance of genetically modified plants, which were put into a curative context,
amongst Clemson University faculty, staff and students. The data collected included
individual perceptions of genetically modified plants in two different contexts using a
Likert rating scale. Participant’s age range, gender, Clemson affiliation (faculty, staff or
student), and major or department was asked. The Clemson University Institutional
Review Board application for the survey outlines these steps (Appendix A).
Participants were approached by an email invitation that contained a link to
SurveyMonkey, a Web based survey program (Appendix B). At SurveyMonkey the
participant read the consent form and checked a box indicating they were willing to
participate in the survey (Appendix C). Then two survey questions were asked followed
by four demographic questions. Data was downloaded as Excel files and charts. One
survey session took approximately 3 minutes. Participants were anonymous and only
identified by age, gender, Clemson affiliation (faculty, staff or student) and major or
department.
An email was sent inviting 1000 faculty, 1000 staff and 5000 students to
participate in the survey, providing them a link to SurveyMonkey. The email invitation
was to be resent after one week if less than 100 responses were received.
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Case Studies
Kalundborg
The town of Kalundborg in Denmark is about 100 km from the capital of
Copenhagen, but this small industrial town is famous in its own right. Kalundborg is
home to the most advanced implementation of the concept of industrial ecology that can
be found worldwide. The field of industrial ecology has developed to focus on creating
linkages between separate industrial activities based on studying the byproducts of one
and the energy or materials (also called feedstocks) required of another (Ehrenfeld and
Gertler 1997, 67-79).
This small town has become the best example of industrial symbiosis, a principle
in the field of industrial ecology where four large industries and the town share materials,
energy and recycle waste materials (Cohen-Rosenthal 2000, 245-264). Although the
arrangement of the four industries is not accidental, the focus of the industrial complex
was not to design an eco-industrial park or to design a system around the principles of
industrial ecology, it was a combination of creative business practices and environmental
awareness (Ehrenfeld and Gertler 1995). The links in the industrial system of Kalundborg
have formed over the past 40 years, and these 11 loop closing links have reduced material
and energy throughput without hindering production or compromising quality (Jacobsen
and Anderberg 2005, 313-335). The system of Kalundborg is complex, but the links are
an important aspect. By focusing on how each is linked to the other and what the cost
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would be if they were not linked, it demonstrates that through creative solutions, these are
still the most sound business decisions.
The initial links in Kalundborg revolve around the sale of waste products, or in
Novo’s case, the removal of waste products at no cost, with little or no processing while
the more recent links focus on the application of new pollution control strategies. These
links alter the by products to make them environmentally benign and resalable,
something that the United States Environmental Protection Agency (EPA) has made
illegal. The Danish EPA has a different approach, looking at waste streams on a case-bycase basis in order to find use for industrial by products. This flexibility has allowed
Kaludborg to house industries that gain financially while promoting environmental
stewardship. As Gertler says, the decision makers in the four companies are profit seekers
as managers but as individuals they are environmentalists(Ehrenfeld and Gertler 1995).

Research Triangle Park
Research Triangle Park was created in 1959 and is considered one of the most
successful research parks in the world (Link 1995). It occupies 6700 acres in the middle
of a triangle formed by UNC Chapel Hill, NC State and Duke. There are over 50 R&D
oriented companies, DuPont, IBM, BASF, GlaxoSmithKline, Novo Nordisk to name a
few of the larger ones, and a host of smaller, more specialized companies. They are
spread through the park in low density, low rise buildings in, as the name suggests, a park
like, wooded setting (Luger and Goldstein 1991).
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In the mid 50s, North Carolina Governor Luther Hodges formed a committee to
investigate how the strengths of the state’s research universities could help North
Carolina’s economy (Link 1995; Link and Scott 2003, 167-175). The committee found
that the 3 universities, Duke, UNC and NC State could attract a concentration of
industrial research labs to the region to take advantage of faculty expertise in their
particular fields. It was an industrialist, Karl Robbins, who was recruited as an investor
that came up with the idea of a park (Luger and Goldstein 1991). He proposed to build a
park on 4000 undeveloped acres between the universities. For almost 10 years, the park
idea was stagnant, but when IBM bough a large site, several more large multinational
companies followed suit (Luger and Goldstein 1991).
Currently because of strict building and site restrictions along with zoning,
smaller start up companies are not longer able to afford space in the park and as a result
growth has slowed. In addition to the lack of start up companies, there has not been
growth from the manufacturing sector (Link 1995; Link and Scott 2003, 167-175). One
of the original goals of the park was to achieve overall statewide economic development
(Luger and Goldstein 1991). There was an expectation that the manufacturing production
of these large R&D companies would locate in the Triangle and provide a large number
of working class employment opportunities in the park. According to Luger and
Goldstein in their book Technology in the Garden, this will not materialize until the state
improves the overall skill and educational levels of non-university trained employees
(Luger and Goldstein 1991).
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The Greenbrier Resort
The Greenbrier Resort was another place that deserved attention. The Greenbrier
is a 6500-acre historic health oriented mineral springs resort (Lund 1996, 11-16). In the
summer of 2011, owner Jim Justice announced plans to further develop the resort’s
healthcare sector by expanding their existing executive clinic into a world class health
institute, saying this "forward-thinking medical initiative…will dramatically impact how
healthcare is delivered around the world” (Cosgrove ).
The area in which the Greenbrier is located was originally Shawnee Indian land,
and the small marsh surrounding the spring was an ideal hunting spot (Conte 1989).
According to Shawnee legend, two young lovers snuck into a valley to escape the notice
of their elders when their chief caught them instead. He shot two arrows, killing the boy
and narrowly missing the girl. A sulphur spring appeared where the second arrow pierced
the ground, and it is said that when the last drop of water is drunk from the spring, her
lover will be brought back to life (Conte 1989). The earliest written account of the
curative powers of the waters come from testimonials from a Mrs. Anderson, who in
1778 was carried 15 miles to the springs in an attempt to cure her rheumatism (Conte
1989). Her recovery over the next few weeks was so complete that word of the curative
powers of the spring spread to others, and many others came to take the “cure” (Conte
1989). After Mrs. Anderson’s visit, a small group of primitive cabins were built around
the spring, beginning the spring’s development into a top rated health resort (Lund 1996,
11-16).
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The evolution of the Greenbrier is interesting: from a Native American swamp to
a grand resort with functions as a hospital during two wars and a “house” for foreign
diplomats in between (Conte 1989), all the while having springs that have a reputation for
having curative properties. The resort has shown that it is multifunctional and adaptive,
though it has a history of financial troubles (Lund 1996, 11-16). In 1947, the Greenbrier
Clinic was created in recognition that many business executives aged prematurely and
that preventative healthcare in a pleasant environment was a sound investment (Lund
1996, 11-16). Moving this idea forward, the current owner, Justice would like to
capitalize on the Greenbrier’s adaptive and multifunctional history and establish a
medical destination focusing on sports performance, wellness, research, product
development, education, cosmetic surgery, and preventive care (Cosgrove 2011).

Epidaruos
The last and oldest case study is the example of a Greek sanctuary outside of the
seaside town of Epidauros. The Sanctuary of Asklepios is steeped in history and
mythology, and its prominence, as a place of healing, is well known. The temple complex
at Epidauros was built as a sanctuary of the god Asklepios. This sanctuary was one of the
most important and revered Askelpieia (Papadakis, Meletzis, and Papadakis 1972), as the
places that Asklepios was said to have healed were known (Gesler 2003). It flourished as
a place of worship and healing from the fifth century B.C. blending spiritual and
therapeutic methods (Burford 1969). The sanctuary outside of Epidauros embodied the
Greek ideal, which called for placement on clear, elevated spots in rural areas. The
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journey from the town to the sanctuary was an important part of the healing process
(Gesler 1993, 171-171). The 15 km journey is rugged and beautiful, and as anthropologist
James Frazer said of his trek in 1890, it has a “pleasing solitariness about it,” (Gesler
1993, 171-171). This shelter along with the ecology of the buildings formed a powerful
healing landscape, a place where the natural, spiritual and built environment combined
contributed to the healing sense of place (Gesler 2005, 295-297).
Through reading the histories of four very different places a few things were
apparent and important for consideration. In Kalundborg, the principles of industrial
ecology are apparent as well as the success of the arrangement, however, newly formed
eco-industrial parks have tried to mimic the symbiosis found in Kalundborg with varying
success (Ehrenfeld and Gertler 1995). In North Carolina at Research Triangle Park, the
park floundered for almost 10 years until IBM announced it would have a large operation
there. In other words, the success of Research Triangle Park hinged on a large name,
well-known corporation locating there (Link 1995). The Greenbrier Resort was built
around its healing springs. It has changed owners several times and its successes have
been up and down. The current owner has plans to make the Greenbrier into the next
destination medical clinic, but questions arise as to whether this is feasible or appropriate
for rural West Virginia (Cosgrove 2011). Finally, the Greek sanctuary of Epidauros was
prominent healing space for centuries, and the important aspect of this case study is how
to relate that sense of healing to a modern landscape (Gesler 1993, 171-171).
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CHAPTER FOUR
GENERAL CONDITIONS
The research on the case studies did not accrue any associated costs. The duration
of the case studies was approximately two months.
The administration of the survey had an associated cost of $25.00/month for the
use of SurveyMonkey Gold. The duration of the survey and the analysis of the results
was approximately two months with one month dedicated to administering the survey and
one month for the analysis.
A possible limitation of the survey is that it was given to a university population
where acceptance of new technologies may be higher. Another possible limitation is that
the case studies are parallel case studies to the proposal. Since this research is focusing on
a new technology, there are no precedents upon which to compare, contrast or improve.
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CHAPTER FIVE
RESULTS
Case Studies
Each of the case studies informed the resulting design guidelines in various ways.
The attached matrix outlines the significance of the case studies.

Figure 2: Case Study Matrix
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Survey
870 respondents completed the survey. A total of 7000 were invited to take the
survey. The random sample was comprised of 1000 faculty, 1000 staff and 5000.
The survey demonstrated that when genetically modified plants are put into a
curative context (i.e. they cure cancer) approval increases dramatically. The first question
sought to determine how the participant felt about genetically modified plants at that
time. The largest portion of respondents, 354 or 40.7% neither supported nor opposed
genetically modified plants. When asked how the participant felt about genetically
modified plants that are used for curative purposes, i.e. to cure specific types of cancer, at
that time, support increased from 26.9% (234 respondents) to 49.8% (433 respondents)
and strong support increased from7% (61 respondents) to 33% (287 respondents).
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Table 1: How do you feel about genetically modified plants (GMPs)?

Table 2: How do you feel about genetically modified plants used for curative purposes (GMPc)?
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The data was then filtered to examine the results by the demographic categories.

Table 3: Gender GMP

Table 4: Gender GMPc
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Table 4: Age GMP

Table 5: Age GMPc
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Table 6: University Status GMP

Table 7: University Status GMPc
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Table 8: University Affiliation GMP

Table 9: University Affiliation GMPc
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Design Guidelines
The case studies and the survey responses resulted in the creation of the following
design guidelines. Each guideline reflects the data gathered. These guidelines listed
below were then applied to the conceptual development along with the final design:
Provide inviting entrances from the main road and through multiple access points along
the greenway.
Provide visual access from the main road and through framing the center from
key points.
Provide office and laboratory space.
Provide visiting scientist housing.
Create a variety of outdoor spaces including small plazas between campus
buildings, interpretive walking trails, demonstration crops and gardens with both
GMPs and traditional medicinal plants and private open space for visiting
scientist housing
Create opportunities for education and illumination by providing educational +
interpretive signage and a visitors center.
Provide security for the crops through the use of attractive yet functional fencing
around the crops.
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Site Inventory and Analysis
Current landscape architecture projects were studied to gain insight and
inspiration for the design of the Clemson Coastal Research and Education Center
(Coastal REC), the site chosen for the design application.

Figure 3: Coastal REC Site Map and Images
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Figure 4: Coastal REC Site Images

Figure 5: Coastal REC Contextual Surroundings Map
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Figure 6: Coastal REC Site Analysis Study
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Precedent Studies
Contemporary landscape architecture projects were studied to gain insight and
inspiration for the design of the Clemson Coastal Research and Education Center
(Coastal REC), the site chosen for the design application.

Figure 7: Park Merced Precedent Study

Figure 8: Viet Village Precedent Study
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Figure 9: Salk Institute Precedent Study

Figure 10: Kresge Foundation Precedent Study
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Conceptual Development
The design guidelines, the site inventory and analysis and the precedent studies
helped derive a concept for the design application focusing on illuminating and revealing
the potential of a new technology using genetically modified plants that have curative
properties. Concept sketches helped define the scope of the design.

Figure 11: Initial Conceptual Sketch

Figure 12: Further Conceptual Development
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Design Application
Conceptual development led to the final design illustrated through perspective
images and plan drawings.

Figure 13: Perspective rendering with views of the research crops and visitor’s center

Figure 14: Campus master plan detailing the response to the design guidelines
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Figure 15: Perspective rendering of the Sacred Grove near the visitor’s center

Figure 16: Enlargement of campus master plan including more detailed response to
the design guidelines
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CHAPTER SIX
CONCLUSION
In a broad sense, this study attempted to discover whether the crux of the problem
of which Richard Florida spoke can be addressed and that is whether a new technology in
plant derived pharmaceuticals could be turned it into a profitable, commercial product.
Specifically, this study aimed to address the issue on perceptions and acceptance of
genetically modified plants when put into a curative context.
It is proposed that this is a viable industry and that the success depends upon three
key points: revealing the potential for the new technology, providing transparency in
process and explaining the benefits while weighing any perceived risk. In this
application, a research and production campus focusing not only on the curative benefits
of genetically modified plants for pharmaceutical but the inherent healing capacity of a
landscape for workers, visitors and the environment as well as the creation of new
industrial activity attempts to address many of the problems faced today.
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Appendix A
Exempt Review Application
Clemson University Institutional Review Board

(Version 10.28.2011)
Clemson University IRB Website
Office use only
Approved

Protocol Number:
Exemption Category ________

______________________________________
Signature of IRB Chair / Designee

_____________________________
Date

1.

Developmental Approval: If you already have developmental approval for this research
study, please give the IRB protocol number assigned to the study. More information available
here.

2.

Research Title:

If different, title used on
consent document(s)
If class project, include
course number and title
3.

Acceptance	
  of	
  genetically	
  modified	
  plants	
  used	
  to	
  
manufacture	
  pharmaceuticals	
  at	
  Clemson	
  University:	
  A	
  	
  
contextual	
  perception	
  survey
LA_891

Principal Investigator (PI): The PI must be a member of the Clemson faculty or staff.
You cannot be the PI if this is your thesis or dissertation. The PI must have completed
IRB-approved human research protections training. Training will be verified by IRB staff
before approval is granted. Training instructions available here. CITI training site available
here.
Name: Ellen	
  A.	
  Vincent
Faculty
Department: Environmental Horticulture,	
  School	
  of	
  AFES
Campus address:
173	
  Poole	
  Ag	
  Center

4.

Staff
E-mail:
ellenav@clemson.edu
Phone: 864-‐656-‐1342
Fax: 864-‐656-‐4960

Co-Investigator(s): Co-Investigators must have completed IRB-approved human research
protections training. Training will be verified by IRB staff before approval is granted.
Training instructions available here. CITI training site available here.
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Name: Susannah	
  Horton
Department: Landscape	
  Architecture,	
  School	
  of	
  PDPLA
Faculty
Staff

Graduate student
Undergraduate student

Name: Matthew	
  Powers
Department: Landscape	
  Architecture,	
  School	
  of	
  PDPLA
Faculty
Staff

5.

Graduate student
Undergraduate student

E-mail:
shorton@clemson.edu
Phone: 805-‐705-‐7624
Other. Please
specify.
E-mail:
powers8@clemson.edu
Phone: (864)-656-4408
Other. Please
specify.

Additional Research Team Members: All research team members must have completed
IRB-approved human research protections training. Training will be verified by IRB staff
before approval is granted. Training instructions available here. CITI training site available
here.
List of additional research team members included. Form available here.

6. Research Team Roles: Describe the role of each member of the research team (everyone
included in Items 3, 4 and 5), indicating which research activities will be carried out by each
particular member. Team members may be grouped into categories.
Description: Ellen Vincent will oversee the development of the survey. Susannah Horton
will create and send the survey. Matthew Powers will serve as an advisor.
7. Email Communications: If you would like one or two of your team members (in addition to
the PI) to be copied on all email communications, please list these individuals in the box
below.
Name: Susannah Horton

E-mail: shorton@clemson.edu

Name:

E-mail:

8. Study Purpose: In non-technical terms, provide a brief description of the purpose of the
study. Upon conclusion of the study, how will you share your results (e.g., academic
publication, evaluation report to funder, conference presentation)?
Description: This survey aims to find the current rate of acceptance of genetically modified
organisms amongst Clemson University students, faculty and staff. These results will aid in
future design decisions when envisioning a new industrial landscape in which genetically
modified organisms, specifically genetically modified plants, have a central role.The results
of this survey will be included in Susannah Horton's final graduate project report.
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9. Anticipated Dates of Research:
Anticipated start date (may not be prior to IRB approval; may be “upon IRB approval”):
Upon IRB approval.
Anticipated completion date (Please include time needed for analysis of individually
identifiable data): 5 weeks
10. Funding Source: Please check all that apply.
Submitted for internal funding
Internally funded
Submitted for external funding
Funding source, if applicable (Do not use initials):
Proposal number (PPN) for the Office of Sponsored Programs:
Name of PI on Funding Proposal:
Externally funded
Funding source, if applicable (Do not use initials):
Proposal number (PPN) for the Office of Sponsored Programs:
Name of PI on Funding Proposal:
Intend to seek funding From whom?
Not funded
11. Support provided by Creative Inquiry Initiative:

Yes

No

If yes, all Creative Inquiry students will be members of the research team, please see item #
5.
12. Other IRB Approvals:
Has this research study been presented to any other IRB?
Where?

Yes

No

When?

If yes, what was their decision?

Approved

Disapproved

Pending

Please attach a copy of any submissions, approvals, or disapprovals from other IRBs.
13. Exempt Review Checklist: To determine whether this study meets the federal requirements
for exemption [45 CFR 46.101], please complete the following checklist. This will indicate if
your study can be exempted from IRB continuing review.
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The Federal Code [45 CFR 46.101] permits research activities in the following six categories
to be exempted. Please check the relevant exemption category / categories.
The Federal Office of Human Research Protections has made Decision Charts available
here to help in determining whether a particular study falls within a particular
Exemption Category.
Categories of Research Activities Exempt from Continuing Review
B1. Research conducted in established or commonly accepted educational settings,
involving normal educational practices, such as:
a. research on regular and special education instructional strategies, OR
b. research on the effectiveness of or the comparison among instructional
techniques, curricula, or classroom management methods.
NOTE: Survey and interview procedures with minors are exemptible if the activities fall
within this category.
B2. Research involving the use of educational tests (cognitive, diagnostic, aptitude,
achievement), survey procedures, interview procedures or observation of public
behavior, UNLESS:
a. the information obtained is recorded in such a manner that human participants
can be identified, directly or through identifiers linked to the participants; AND
b. any disclosure of the human participants’ responses outside the research could
reasonably place the participants at risk of criminal or civil liability or be
damaging to the participants’ financial standing, employability, or reputation.
NOTE: Survey and interview techniques which include minors are not exempt.
Observation of the public behavior of minors, if the researcher is not a
participant, is exempt.
B3. Research involving the use of educational tests (cognitive, diagnostic, aptitude,
achievement), survey procedures, interview procedures, or observation of public
behavior that is not exempt under Category B2, if:
a. the human participants are elected or appointed public officials or candidates for
public office, or
b. federal statute(s) require(s) without exception that the confidentiality of the
personally identifiable information will be maintained throughout the research
and thereafter.
B4. Research, involving the collection or study of existing data, documents, records,
pathological specimens, or diagnostic specimens, if these sources are publicly
available or if the information is recorded by the investigator in such a manner that
participants cannot be identified directly or through identifiers linked to the
participants.
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B5. NOTE: Please contact the IRB office before selecting this category since use of
this exemption must be initiated by the agency head of the federal funder.
Research and demonstration projects which are conducted by or subject to the
approval of appropriate Federal Department or Agency heads, and which are
designed to study, evaluate, or otherwise examine:
a. public benefit or service programs; or
b. procedures for obtaining benefits or services under those programs; or
c. possible changes in or alternatives to those programs or procedures; or
d. possible changes in methods or levels of payment for benefits or services under
those programs.
B6. Taste and food quality evaluation and consumer acceptance studies,
a. if wholesome foods without additives are consumed, OR
b. if a food is consumed that contains a food ingredient at or below the level and
for a use found to be safe, or agricultural chemical or environmental
contaminant at or below the level found to be safe, by the Food and Drug
Administration or approved by the Environmental Protection Agency or the
Food Safety and Inspection Service of the U.S. Department of Agriculture.

14. If you selected Exemption Category B4, please complete questions a through h
below:
a. What are the types of data or specimens?
b. What is the source of the data or specimens?
c. Are the data or specimens publicly available? (That is, can the general public obtain
the data or specimens? Data are not considered publicly available if access is limited
to researchers.)
Yes
No
If yes, please contact the IRB staff for consultation. You may not be conducting
research involving human subjects as defined in the federal regulations governing
research involving human subjects (45 CFR 46.102).
d. If the data or specimens are not publicly available, how are you obtaining permission
to access these or to use them for research purposes?
Please attach a copy of the correspondence or agreement granting you permission.
e. How will the data be made available to you (e.g., electronic file, access to hard copy
records at record-holder’s institution)?
f. How are the data or specimens identified when they are made available to you?
1)
Direct Identifier (e.g., subject name, address, or social security number).
2)
Indirect Identifier (e.g., an assigned code that could be used by the
investigator or the source providing the data or specimens to identify a
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3)

subject, such as a pathology tracking number or a tracking code used by the
source).
If you will receive data with indirect identifiers only, please contact the IRB
staff for consultation. You may not be conducting research involving human
subjects as defined in the federal regulations governing research involving
human subjects (45 CFR 46.102).
No Identifier (i.e., neither the researcher nor the source providing the data or
specimens can identify a subject based upon information provided with the
data or specimens).
If it will be impossible for anyone to identify subjects based upon information
provided with the data or specimens, you will not be conducting research
involving human subjects as defined in the federal regulations governing
research involving human subjects (45 CFR 46). Please contact the IRB staff
for confirmation.

g. If (1) is checked above, will you record any direct identifiers that are available to you?
Yes*
No
h. Will any data or specimens be collected from participants after the submission of this
application? (Data or specimens are considered to “exist” if ALL the data or
specimens to be used for the research have been collected prior to the submission of
this application.)
Yes*
No
*Your research does not qualify for exemption from IRB review under Exemption
Category B4.
PLEASE NOTE: If you are applying for exemption only under Exemption Category B4,
you have now completed this application. Please submit your application following the
instructions at the end of the form.

15. Study Sample: (Groups specifically targeted for study)
Describe the participants you plan to recruit and the criteria used in the selection process.
Indicate if there are any special inclusion or exclusion criteria.
NOTE: If individuals who are incarcerated will be participants, your research is not
exemptible. Please complete the Expedited / Full Review Application.
Description: Clemson	
  University	
  community:	
  faculty,	
  staff	
  and	
  students	
  18	
  years	
  and	
  
older	
  of	
  Clemson	
  University.
Age range of participants: 18	
  and	
  older

Projected number of participants: 110
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Employees

Minors (under 18) *
Student
s

Pregnant women *

Fetuses
/ neonates
*

Educationally / economically disadvantaged *

Minors who are wards of the
state, or any other agency,
institution, or entity *

Individuals who are incarcerated *

Other–specify:

Military personnel

Persons incompetent to give valid consent *

*State necessity for using this type of participant:
16. Study Locations:
Clemson University

Other University / College

School System / Individual Schools

Other – specify

You may need to obtain permission if participants will be recruited or data will be obtained
through schools, employers, or community organizations. Are you required to obtain
permission to gain access to people or to access data that are not publicly available? If yes,
provide a research site letter from a person authorized to give you access to the participants or
to the data. Guidance regarding Research Site Letters is available here.
Research Site Letter(s) not required.
Research Site Letter(s) attached.
Research Site Letter(s) pending and will be provided when obtained.
17. Recruitment Method:
Describe how research participants will be recruited in the study. How will you identify
potential participants? How will you contact them? Attach a copy of any material you will
use to recruit participants (e.g., advertisements, flyers, telephone scripts, verbal
recruitment, cover letters, or follow-up reminders).
Description: A campus wide email will be sent inviting people to participate in the survey,
providing them a link to SurveyMonkey. The email invitation will be resent after one week if
less than 100 responses are received.
18. Participant Incentives:
a. Will you pay participants?
Amount: $

Yes

No

When will money be paid?:
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b. Will you give participants incentives / gifts / reimbursements?

Yes

No

Describe incentives / gifts / reimbursements:
Value of incentives / gifts / reimbursements: $
When will incentives / gifts / reimbursements be given?:
c. Will participants receive course credit?
d. Will participants receive extra credit?

Yes
Yes

No
No

If yes, an equivalent alternative to research participation must be provided and
described in your informed consent document(s).
19. Informed Consent:
a. Attach a copy of the informational letter or consent script you plan to provide to your
participants (and their parents or guardians, if applicable). Consent Document

Templates
b. Will you use concealment (incomplete disclosure) or deception in this study?
Yes
No
If yes, please see guidance regarding Research Involving Deception or Concealment
here, submit a copy of the Additional Pertinent Information / Permission for Use of
Data Collected in a Research Study form you will use, and provide a justification in
the following space for this use of concealment or deception.
20. Procedures:
a.

What data will you collect? Individual	
  perception's	
  of	
  genetically	
  modified	
  plant	
  
organisms	
  in	
  two	
  different	
  contexts	
  using	
  a	
  Likert	
  rating	
  scale.	
  Participant's	
  age	
  
range;	
  gender;	
  Clemson	
  affililation	
  as	
  student,	
  staff,	
  	
  faculty,	
  or	
  alumnus;	
  and	
  
major	
  or	
  department	
  will	
  be	
  asked.	
  	
  

b. Please describe in detail the process each participant will experience and how you
will obtain the data. Participants	
  will	
  be	
  approached	
  by	
  an	
  email	
  invitation	
  that	
  
contains	
  a	
  link	
  to	
  SurveyMonkey,	
  a	
  Web	
  based	
  survey	
  program.	
  At	
  
SurveyMonkey	
  the	
  participant	
  will	
  read	
  the	
  consent	
  form	
  and	
  check	
  a	
  box	
  	
  
indicating	
  they	
  are	
  willing	
  to	
  participate	
  in	
  the	
  survey.	
  Then	
  two	
  survey	
  
quesitons	
  will	
  be	
  asked	
  followed	
  by	
  	
  four	
  demographic	
  questions.	
  	
  Data	
  will	
  be	
  
downloaded	
  as	
  Excel	
  files	
  and	
  charts.
c.

How many participation sessions and how much time will be required for each
participant, including follow up sessions? 1	
  session	
  will	
  take	
  approximately	
  3	
  
minutes.

d. How will you collect data?
in-person contact
telephone
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snail mail
website

email
other, describe

Please include copies of surveys, interview questions, data collection tools and
debriefing statements. If survey or interview questions have not been fully developed,
provide information on the types of questions to be asked, or a description of the
parameters of the survey / interview. Please note: finalized survey or interview
instruments will need to be reviewed and approved by amendment, before
implementation.
e. Will you audio record participants?
Yes
No
f. Will you video record participants?
Yes
No
g. Will you photograph participants?
Yes
No
If you will audio or video record or take identifiable photographs of participants,
please consult the IRB’s Guidance on the Use of Audio / Video Recording and
Photography here. Please include all the information addressed by this guidance
document in the application and, where appropriate, in the consent document(s).
21. Protection of Confidentiality: Describe the security measures you will take to protect the
confidentiality of the information obtained. Will participants be identifiable either by name or
through demographic data? If yes, how will you protect the identity of the participants and
their responses? Where will the data be stored and how will it be secured? Who will have
access to the data? How will identifiers be maintained or destroyed after the study is
completed?
Description: Participants	
  will	
  be	
  anonymous	
  and	
  only	
  identified	
  by	
  age,	
  gender,	
  	
  and	
  
Clemson	
  affiliation	
  (student,	
  staff,	
  or	
  faculty)	
  and	
  major	
  or	
  department.	
  	
  
22. PI Signature:
I have reviewed this research protocol and the informed consent document(s), if applicable. I
request approval of this research study by the IRB of Clemson University.
Conflict of Interest Statement:
Could the results of the study provide an actual or potential financial gain to you, a
member of your family, or any of the co-investigators, or give the appearance of a
potential conflict of interest?
No.
Yes. I agree to disclose any actual or potential conflict of interest prior to IRB
action on this study.
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_____________________________________________
________________________
Signature of Principal Investigator
Date
(hard-copy signature only needed if application will not be submitted via PI’s email account)

Submission Instructions: Exempt applications are processed as received. There is no deadline
for submitting exempt applications for review. Please allow seven to ten business days for
processing.
Please submit this application and all associated documents from the Principal Investigator’s
(PI’s) email address to the IRB staff. Receipt of the application electronically from the PI will
qualify the application as a signed electronic submission. Alternatively, the signed, hard-copy
application may be mailed or delivered to the Office of Research Compliance, 223 Brackett Hall,
Clemson, SC 29634-5704.
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Appendix B
Clemson University Contextual Perception Survey
of Genetically Modified Plants
	
  

[Email text:]
Subject: Request to participate in student survey
My name is Susannah Horton, and I’m a graduate student working on my final project in
landscape architecture. I would like to know how you feel about genetically modified
organisms (GMOs).
This survey should take approximately three minutes, and with your input I will be able
to find out what the current opinion at Clemson University is on this subject.
[At SurveyMonkey:]
[Consent form appears as front page with box to check at bottom that indicates an
informed willingness to participate in the survey.]
Thank you for your willingness to participate in this survey.
Please select one answer for each question.
Please answer every question.

1. How do you feel about genetically modified plants right now?
1. Strongly support
2. Support
3. Neither support nor oppose
4. Opposed
5. Strongly opposed
6. No opinion
2. How do you feel about genetically modified plants that are used for curative
purposes, i.e. to cure specific types of cancer, right now?
1. Strongly support
2. Support
3. Neither support nor oppose
4. Opposed
5. Strongly opposed
6. No opinion
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Demographics
1. Gender
Male
Female
2. Age

Which of the following age categories describes you:
18-24
25-34
35-44
45-54
55-64
65 or over

3. Please check the affiliation that best describes you:
Student
Faculty
Staff
Alumnus
4. Major, Degree or Department you are most closely associated with:
Please enter your answer on the line
____________________________________________________

Thank you for your time today. We are most grateful.
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Appendix C
Information about Being in a Research Study
Clemson University
Clemson University Contextual Perception Survey of Genetically Modified Plants
Description of the Study and Your Part in It
Susannah Horton and Dr. Ellen Vincent at Clemson University are inviting you to take
part in a research study. Susannah Horton is a student at Clemson University, running this
study with the help of Dr. Vincent, an instructor at Clemson University. The purpose of
this research is to understand how people feel about genetically modified organisms
(GMOs) at this time.
Your part in the study will be to answer two questions about GMOs and to answer several
demographic questions.
It will take you about three minutes to be in this study.
Risks and Discomforts
We do not know of any risks or discomforts to you in this research study.
Possible Benefits
We do not know of any way you would benefit directly from taking part in this study.
However, this research may help us to understand peoples’ present perceptions of GMOs.
Extra credit will offered to Dr. Vincent’s horticulture and forestry classes. A nonresearch opportunity for the same amount of extra credit that involves the same effort and
time investment will be available and posted on Blackboard.
Protection of Privacy and Confidentiality
Your contribution to this survey will be anonymous. No identifying data linking you to
your answers is available.
Choosing to Be in the Study
You do not have to be in this study. You may choose not to take part and you may choose
to stop taking part at any time. You will not be punished in any way if you decide not to
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be in the study or to stop taking part in the study. If you decide not to take part or to stop
taking part in this study, it will not affect your grade in any way.
Contact Information
If you have any questions or concerns about this study or if any problems arise, please
contact Dr. Ellen Vincent at 864-656-1342 or Susannah Horton at 805-‐705-‐7624	
  at
Clemson University. If you have any questions or concerns about your rights in this
research study, please contact the Clemson University Office of Research Compliance
(ORC) at 864-656-6460 or irb@clemson.edu. If you are outside of the Upstate South
Carolina area, please use the ORC’s toll-free number, 866-297-3071.
Consent (check box below if you agree to participate)
_I have read this form and I agree to take part in this study.
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